Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors

ABSTRACT Highly active antiretroviral therapy (HAART) consists of a combination of drugs to achieve maximal virological response and reduce the potential for the emergence of antiviral resistance. Despite being the first antivirals described to be effective against HIV, reverse transcriptase inhibitors remain the cornerstone of HAART. There are two broad classes of reverse transcriptase inhibitor, the nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). Since the first such compounds were developed, viral resistance to them has inevitably been described; this necessitates the continuous development of novel compounds within each class. In this review, we consider the NRTIs and NNRTIs currently in both preclinical and clinical development or approved for second-line therapy and describe the patterns of resistance associated with their use as well as the underlying mechanisms that have been described. Due to reasons of both affordability and availability, some reverse transcriptase inhibitors with a low genetic barrier are more commonly used in resource-limited settings. Their use results in the emergence of specific patterns of antiviral resistance and so may require specific actions to preserve therapeutic options for patients in such settings.

[1]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[2]  M. Leal,et al.  [Resistance to nucleoside reverse transcriptase inhibitors]. , 2001, Enfermedades infecciosas y microbiologia clinica.

[3]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[4]  M. Wainberg,et al.  Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes , 2010, Antimicrobial Agents and Chemotherapy.

[5]  A. Rieger,et al.  Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve Subjects , 2010, Antimicrobial Agents and Chemotherapy.

[6]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[7]  Andrea De Luca,et al.  Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. , 2002, AIDS research and human retroviruses.

[8]  S. Sarafianos,et al.  Mechanism of Interaction of Human Mitochondrial DNA Polymerase γ with the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Indicates a Low Potential for Host Toxicity , 2011, Antimicrobial Agents and Chemotherapy.

[9]  J. Mellors,et al.  Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase , 2007, AIDS.

[10]  J. Mellors,et al.  In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine , 2000, Antimicrobial Agents and Chemotherapy.

[11]  P. Selhorst,et al.  Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides , 2011, Antimicrobial Agents and Chemotherapy.

[12]  R. Paredes,et al.  Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. , 2008, The Journal of antimicrobial chemotherapy.

[13]  M. Wainberg,et al.  In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine , 2011, Antimicrobial Agents and Chemotherapy.

[14]  M. Wainberg,et al.  Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. , 2010, The Journal of antimicrobial chemotherapy.

[15]  S. Sarafianos,et al.  Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor* , 2009, The Journal of Biological Chemistry.

[16]  F. Bushman,et al.  Retroviral DNA integration directed by HIV integration protein in vitro. , 1990, Science.

[17]  E. R. Pascuet,et al.  Papel actual de tenofovir en la clínica , 2008 .

[18]  R. Paredes,et al.  Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens , 2011, Antimicrobial Agents and Chemotherapy.

[19]  R. Shattock,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor , 2008, Antimicrobial Agents and Chemotherapy.

[20]  Joel E Gallant,et al.  Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance , 2002, Antiviral therapy.

[21]  C. Torti,et al.  Prevalence and Risk Factors for Etravirine Resistance among Patients Failing on Non-Nucleoside Reverse Transcriptase Inhibitors , 2008, Antiviral therapy.

[22]  E. De Clercq,et al.  Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections , 2007, Antimicrobial Agents and Chemotherapy.

[23]  K. Robinson,et al.  Mechanism of Active Renal Tubular Efflux of Tenofovir , 2006, Antimicrobial Agents and Chemotherapy.

[24]  M. Ekstrand,et al.  Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance , 2011, AIDS.

[25]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[26]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[27]  K. Borroto-Esoda,et al.  Dioxolane Guanosine, the Active Form of the Prodrug Diaminopurine Dioxolane, Is a Potent Inhibitor of Drug‐Resistant HIV‐1 Isolates From Patients for Whom Standard Nucleoside Therapy Fails , 2002, Journal of acquired immune deficiency syndromes.

[28]  M. Wainberg,et al.  Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations , 2009, Antimicrobial Agents and Chemotherapy.

[29]  B. Clotet,et al.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial , 2011, The Lancet.

[30]  William A. Lee,et al.  Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue , 2005, Antimicrobial Agents and Chemotherapy.

[31]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[32]  R. Schinazi,et al.  Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals , 2010, Antiviral therapy.

[33]  P. Kaleebu,et al.  Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1 , 2011, Antimicrobial Agents and Chemotherapy.

[34]  G. di Perri,et al.  Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2 , 2010, HIV clinical trials.

[35]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[36]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[37]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[38]  F. Uckun,et al.  Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase , 2006, Journal of enzyme inhibition and medicinal chemistry.

[39]  J. Turgeon,et al.  Multiple-Dose Pharmacokinetic Behavior of Elvucitabine, a Nucleoside Reverse Transcriptase Inhibitor, Administered over 21 Days with Lopinavir-Ritonavir in Human Immunodeficiency Virus Type 1-Infected Subjects , 2008, Antimicrobial Agents and Chemotherapy.

[40]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). , 2001, Bioorganic & medicinal chemistry letters.

[41]  S. Thrall,et al.  Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. , 1997, Biochemistry.

[42]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[43]  D. Ward,et al.  Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis , 2007, AIDS.

[44]  Huldrych F Günthard,et al.  2011 update of the drug resistance mutations in HIV-1. , 2011, Topics in antiviral medicine.

[45]  Anneke Raney.  Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-resistance to Other NNRTIs , 2008 .

[46]  E. Poveda,et al.  Raltegravir and etravirine are active against HIV type 1 group O. , 2009, AIDS research and human retroviruses.

[47]  R. Ptak,et al.  Development of Hexadecyloxypropyl Tenofovir (CMX157) for Treatment of Infection Caused by Wild-Type and Nucleoside/Nucleotide-Resistant HIV , 2010, Antimicrobial Agents and Chemotherapy.

[48]  E. Poveda,et al.  Europe and Asia , 2022 .

[49]  M. Wainberg,et al.  Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination , 2011, AIDS.

[50]  B. Clotet,et al.  Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis , 2012, Journal of acquired immune deficiency syndromes.

[51]  Yvonne Jones,et al.  High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.

[52]  Koen Andries,et al.  TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[53]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[54]  R. Mackman,et al.  Intracellular Metabolism of the Nucleotide Prodrug GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent , 2007, Antimicrobial Agents and Chemotherapy.

[55]  S. Sarafianos,et al.  2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. , 2008, The international journal of biochemistry & cell biology.

[56]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[57]  L. Bacheler,et al.  The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations , 2006, Journal of Virology.

[58]  A. Nel,et al.  Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. , 2010, AIDS research and human retroviruses.

[59]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[60]  E. De Clercq,et al.  Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections , 2007, Antimicrobial Agents and Chemotherapy.

[61]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[62]  R. Haubrich,et al.  Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials , 2010, Antiviral therapy.

[63]  V. Calvez,et al.  Emerging Mutations and Associated Factors in Patients Displaying Treatment Failure on An Etravirine-Containing Regimen , 2012, Antiviral therapy.

[64]  R. Haubrich,et al.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.

[65]  Robert A. Domaoal,et al.  Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. , 2004, The international journal of biochemistry & cell biology.

[66]  W. Chantratita,et al.  Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[67]  V. Calvez,et al.  Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes , 2009, Antimicrobial Agents and Chemotherapy.

[68]  Tommy F. Liu,et al.  Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors , 2009, Journal of acquired immune deficiency syndromes.

[69]  Roger Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[70]  E. Poveda,et al.  Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database , 2010, AIDS.

[71]  J. Vingerhoets,et al.  Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine , 2011, Journal of acquired immune deficiency syndromes.

[72]  C. Petropoulos,et al.  Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance , 2010, Antimicrobial Agents and Chemotherapy.

[73]  D. Richman,et al.  Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. , 2010, AIDS research and human retroviruses.

[74]  A. Wood,et al.  Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 , 2010, Antimicrobial Agents and Chemotherapy.

[75]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) , 2001 .

[76]  Dirk Jochmans,et al.  TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 , 2009, Antimicrobial Agents and Chemotherapy.

[77]  M. Matsuoka,et al.  4′-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro , 2001, Antimicrobial Agents and Chemotherapy.

[78]  Hilde Azijn,et al.  Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies , 2010, AIDS.

[79]  K. Ruxrungtham,et al.  Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor‐naïve, nonnucleoside reverse transcriptase inhibitor‐experienced patients: study TMC125‐C227 * , 2008, HIV medicine.

[80]  C. Katlama,et al.  HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy , 2000, AIDS.

[81]  K. White,et al.  Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131 , 2007, Antimicrobial Agents and Chemotherapy.

[82]  A S Perelson,et al.  Drug concentration heterogeneity facilitates the evolution of drug resistance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[83]  M. Wainberg,et al.  HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture , 2006 .

[84]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[85]  S. Kapiga,et al.  Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women , 2009, AIDS.

[86]  M. Wainberg,et al.  A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors , 2003, AIDS.

[87]  M. de Béthune,et al.  Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. , 2010, AIDS research and human retroviruses.